Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -12% Improvement Relative Risk Ventilation 16% ICU admission 28% Severe case -68% c19early.org/d Davoudi et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 153 patients in Iran (February - March 2020) Higher severe cases with higher vitamin D levels (not stat. sig., p=0.3) Davoudi et al., BMC Infectious Diseases, doi:10.1186/s12879-021-06168-7 Favors vitamin D Favors control
Lack of association between vitamin D insufficiency and clinical outcomes of patients with COVID-19 infection
Davoudi et al., BMC Infectious Diseases, doi:10.1186/s12879-021-06168-7
Davoudi et al., Lack of association between vitamin D insufficiency and clinical outcomes of patients with COVID-19 infection, BMC Infectious Diseases, doi:10.1186/s12879-021-06168-7
May 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 153 hospitalized patients in Iran, showing no significant difference in outcomes based on vitamin D levels. Adjusted results are only provided for vitamin D as a continuous variable. This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups.
risk of death, 12.3% higher, RR 1.12, p = 1.00, high D levels (≥30ng/mL) 2 of 57 (3.5%), low D levels (<30ng/mL) 3 of 96 (3.1%).
risk of mechanical ventilation, 15.8% lower, RR 0.84, p = 1.00, high D levels (≥30ng/mL) 1 of 57 (1.8%), low D levels (<30ng/mL) 2 of 96 (2.1%), NNT 304.
risk of ICU admission, 27.8% lower, RR 0.72, p = 0.74, high D levels (≥30ng/mL) 3 of 57 (5.3%), low D levels (<30ng/mL) 7 of 96 (7.3%), NNT 49.
risk of severe case, 68.4% higher, RR 1.68, p = 0.30, high D levels (≥30ng/mL) 9 of 57 (15.8%), low D levels (<30ng/mL) 9 of 96 (9.4%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Davoudi et al., 18 May 2021, retrospective, Iran, peer-reviewed, 11 authors, study period February 2020 - March 2020.
Contact: fkani63@gmail.com (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Davoudi et al. BMC Infectious Diseases (2021) 21:450 https://doi.org/10.1186/s12879-021-06168-7 RESEARCH Open Access Lack of association between vitamin D insufficiency and clinical outcomes of patients with COVID-19 infection Alireza Davoudi1, Narges Najafi1, Mohsen Aarabi2, Atefeh Tayebi1, Roja Nikaeen3, Hamideh Izadyar1, Zahra Salar4, Leila Delavarian1, Narges Vaseghi5, Zahra Daftarian1 and Fatemeh Ahangarkani1* Abstract Background: A protective effect of vitamin D against COVID-19 infection is under investigation. We aimed to analyze the effect of vitamin D sufficiency on the clinical outcomes of patients infected with COVID-19. Methods: In this cross-sectional study we analyzed the vitamin D levels of COVID-19 patients who were admitted to Razi Hospital (an infectious disease referral center in Mazandaran province in northern Iran) from February to March 2020. Overall, a cutoff point of 30 ng/mL was used for the definition of vitamin D sufficiency. Results: One hundred fifty-three patients were analyzed in this study who had laboratory documentation of a 25(OH) D level at the time of hospitalization. The vitamin D levels of the patients were 27.19 ± 20.17 ng/mL. In total, 62.7% (n = 96) of the patients had a 25(OH) D level of less than 30 ng/mL and 37.25% (n = 57) had a 25(OH) D level of more than 30 ng/mL. In total, 49% (n = 75) of the patients suffered from at least one underlying disease. The univariate and multivariable regression showed that vitamin D sufficiency was not associated with a statistically significant lower risk of adverse clinical outcomes of COVID-19 such as duration of hospitalization and severity of infection (P > 0.05). Conclusions: Sufficient vitamin D levels were not found to be protective against adverse clinical outcomes in patients infected with COVID-19. Chronic disorders in COVID-19 patients were found to have greater relevance than vitamin D levels in determining the adverse outcomes of the infection. Further studies are needed to determine the role of vitamin D level in predicting the outcomes of COVID-19 infection. Keywords: Vitamin D, SARS-CoV-2, COVID-19, Coronavirus, Sufficiency, Insufficiency
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit